Michele P Lambert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7390974/publications.pdf

Version: 2024-02-01

139 papers	5,085 citations	109321 35 h-index	98798 67 g-index
141 all docs	141 docs citations	141 times ranked	8390 citing authors

#	Article	IF	Citations
1	Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nature Medicine, 2014, 20, 1315-1320.	30.7	483
2	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. American Journal of Human Genetics, 2017, 100, 75-90.	6.2	343
3	Thrombocytopenia following Pfizer and Moderna <scp>SARSâ€CoV</scp>â€2 vaccination. American Journal of Hematology, 2021, 96, 534-537.	4.1	331
4	Clinical updates in adult immune thrombocytopenia. Blood, 2017, 129, 2829-2835.	1.4	315
5	Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood, 2016, 127, 17-28.	1.4	165
6	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood, 2016, 127, 2791-2803.	1.4	157
7	Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematology,the, 2015, 2, e315-e325.	4.6	146
8	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066.	6.2	137
9	A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood, 2016, 127, 2903-2914.	1.4	121
10	Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. Genome Medicine, 2015, 7, 36.	8.2	119
11	Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. Journal of Allergy and Clinical Immunology, 2019, 143, 1482-1495.	2.9	116
12	Neutrophil accumulation and NET release contribute to thrombosis in HIT. JCI Insight, 2018, 3, .	5.0	115
13	Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood, 2007, 110, 1153-1160.	1.4	107
14	What is new with 22q? An update from the 22q and You Center at the Children's Hospital of Philadelphia. American Journal of Medical Genetics, Part A, 2018, 176, 2058-2069.	1.2	106
15	Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Advances, 2020, 4, 6051-6063.	5.2	105
16	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica, 2017, 102, 1192-1203.	3.5	92
17	A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies. Science Translational Medicine, 2016, 8, 328ra30.	12.4	87
18	Defects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg2+ homeostasis and cytoskeletal architecture. Nature Communications, 2016, 7, 11097.	12.8	84

#	Article	IF	Citations
19	Challenges and promises for the development of donor-independent platelet transfusions. Blood, 2013, 121, 3319-3324.	1.4	78
20	Eltrombopag for use in children with immune thrombocytopenia. Blood Advances, 2018, 2, 454-461.	5.2	75
21	Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica, 2020, 105, 888-894.	3.5	75
22	Diagnosis and Management of Autoimmune Cytopenias in Childhood. Pediatric Clinics of North America, 2013, 60, 1489-1511.	1.8	74
23	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatric Blood and Cancer, 2016, 63, 1407-1413.	1.5	70
24	Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. Journal of Allergy and Clinical Immunology, 2019, 143, 258-265.	2.9	68
25	A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatric Blood and Cancer, 2008, 50, 223-226.	1.5	66
26	High-level transgene expression in induced pluripotent stem cellâ€“derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood, 2014, 123, 753-757.	1.4	54
27	Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptorâ€“related protein 1 (LRP1) on megakaryocytes. Blood, 2009, 114, 2290-2298.	1.4	51
28	RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion, 2012, 52, 1126-1136.	1.6	49
29	GNE variants causing autosomal recessive macrothrombocytopenia without associated muscle wasting. Blood, 2018, 132, 1851-1854.	1.4	48
30	The 22q11.2 deletion syndrome: Cancer predisposition, platelet abnormalities and cytopenias. American Journal of Medical Genetics, Part A, 2018, 176, 2121-2127.	1.2	47
31	Chemokines and thrombogenicity. Thrombosis and Haemostasis, 2007, 97, 722-729.	3.4	43
32	Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. Nature Communications, 2021, 12, 7222.	12.8	41
33	Platelets in liver and renal disease. Hematology American Society of Hematology Education Program, 2016, 2016, 251-255.	2.5	39
34	Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge. Blood, 2007, 110, 1903-1905.	1.4	38
35	Myosin-II repression favors pre/proplatelets but shear activation generates platelets and fails in macrothrombocytopenia. Blood, 2015, 125, 525-533.	1.4	38
36	Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding. Blood, 2017, 130, 1026-1030.	1.4	38

#	Article	IF	Citations
37	Secondâ€line treatments in children with immune thrombocytopenia: Effect on platelet count and patientâ€centered outcomes. American Journal of Hematology, 2019, 94, 741-750.	4.1	37
38	Convalescent plasma for pediatric patients with SARSâ€CoVâ€2â€associated acute respiratory distress syndrome. Pediatric Blood and Cancer, 2020, 67, e28693.	1.5	37
39	What To Do When You Suspect an Inherited Platelet Disorder. Hematology American Society of Hematology Education Program, 2011, 2011, 377-383.	2.5	33
40	Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia. American Journal of Hematology, 2017, 92, E88-E91.	4.1	33
41	AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6. Molecular Therapy - Methods and Clinical Development, 2018, 10, 291-302.	4.1	33
42	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. American Journal of Hematology, 2018, 93, 882-888.	4.1	30
43	22q and two: 22q11.2 deletion syndrome and coexisting conditions. American Journal of Medical Genetics, Part A, 2018, 176, 2203-2214.	1.2	30
44	Nextâ€generation sequencing for the diagnosis ofMYH9â€RD: Predicting pathogenic variants. Human Mutation, 2020, 41, 277-290.	2.5	30
45	Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatric Blood and Cancer, 2012, 58, 221-225.	1.5	29
46	Utility of the immature platelet fraction in pediatric immune thrombocytopenia: Differentiating from bone marrow failure and predicting bleeding risk. Pediatric Blood and Cancer, 2018, 65, e26812.	1.5	27
47	Multicenter Cohort Study Comparing U.S. Management of Inpatient Pediatric Immune Thrombocytopenia to Current Treatment Guidelines. Pediatric Blood and Cancer, 2016, 63, 1227-1231.	1.5	26
48	Inherited Platelet Disorders. Hematology/Oncology Clinics of North America, 2019, 33, 471-487.	2.2	25
49	A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation. Journal of Clinical Investigation, 2015, 126, 483-494.	8.2	25
50	Chemotherapy induced thrombocytopenia in pediatric oncology. Critical Reviews in Oncology/Hematology, 2016, 99, 299-307.	4.4	24
51	Utility and limitations of exome sequencing in the molecular diagnosis of pediatric inherited platelet disorders. American Journal of Hematology, 2018, 93, 8-16.	4.1	22
52	Common variable immunodeficiencyâ€“associated endotoxemia promotes early commitment to the T follicular lineage. Journal of Allergy and Clinical Immunology, 2019, 144, 1660-1673.	2.9	22
53	Dysregulation of PLDN (pallidin) is a mechanism for platelet dense granule deficiency in RUNX1 haplodeficiency. Journal of Thrombosis and Haemostasis, 2017, 15, 792-801.	3.8	21
54	Influence of the American Society of Hematology Guidelines on the Management of Newly Diagnosed Childhood Immune Thrombocytopenia. JAMA Pediatrics, 2014, 168, e142214.	6.2	20

#	Article	IF	Citations
55	Apoptotic effects of platelet factorÂVIII on megakaryopoiesis: implications for a modified human FVIII for plateletâ€based gene therapy. Journal of Thrombosis and Haemostasis, 2014, 12, 2102-2112.	3.8	20
56	Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel. Blood Advances, 2021, 5, 414-431.	5.2	19
57	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	3.8	19
58	Sports Participation in Children and Adolescents with Immune Thrombocytopenia (ITP). Pediatric Blood and Cancer, 2015, 62, 2223-2225.	1.5	18
59	Fatigue in children and adolescents with immune thrombocytopenia. British Journal of Haematology, 2020, 191, 98-106.	2.5	18
60	A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia. American Journal of Hematology, 2012, 87, 532-534.	4.1	17
61	Defective RAB1B-related megakaryocytic ER-to-Golgi transport in RUNX1 haplodeficiency: impact on von Willebrand factor. Blood Advances, 2018, 2, 797-806.	5.2	17
62	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cellâ€“Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. Clinical Cancer Research, 2022, 28, 3804-3813.	7.0	17
63	Intramedullary megakaryocytes internalize released platelet factor 4 and store it in alpha granules. Journal of Thrombosis and Haemostasis, 2015, 13, 1888-1899.	3.8	16
64	Current status of blood â€˜pharmingâ€™. Current Opinion in Hematology, 2017, 24, 565-571.	2.5	16
65	The Role of Platelet Factor 4 in Radiation-Induced Thrombocytopenia. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1533-1540.	0.8	15
66	Distinct immune trajectories in patients with chromosome 22q11.2 deletion syndrome and immune-mediated diseases. Journal of Allergy and Clinical Immunology, 2022, 149, 445-450.	2.9	15
67	The incidence of thrombocytopenia in children with Cornelia de Lange syndrome. American Journal of Medical Genetics, Part A, 2011, 155, 33-37.	1.2	14
68	Update on the inherited platelet disorders. Current Opinion in Hematology, 2015, 22, 460-466.	2.5	13
69	Population based frequency of naturally occurring lossâ€ofâ€function variants in genes associated with platelet disorders. Journal of Thrombosis and Haemostasis, 2021, 19, 248-254.	3.8	13
70	Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 69-80.	2.3	13
71	2-O, 3-O-Desulfated Heparin (ODSH) Mitigates Chemotherapy-Induced Thrombocytopenia (CIT) by Blocking the Negative Paracrine Effect of Platelet Factor 4 (PF4) On Megakaryopoiesis. Blood, 2012, 120, 386-386.	1.4	13
72	Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Pediatric Blood and Cancer, 2021, 68, e29026.	1.5	11

#	Article	IF	Citations
73	Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS). Expert Review of Clinical Immunology, 2021, 17, 1163-1173.	3.0	11
74	Diagnostic Challenges in Pediatric Hemophagocytic Lymphohistiocytosis. Journal of Clinical Immunology, 2021, 41, 1213-1218.	3.8	10
75	Rapid Evaluation of Platelet Function With T2 Magnetic Resonance. American Journal of Clinical Pathology, 2016, 146, 681-693.	0.7	9
76	2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia. Blood Advances, 2018, 2, 754-761.	5.2	9
77	Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation. European Journal of Haematology, 2021, 106, 783-787.	2.2	9
78	Platelets and eltrombopag: a not-so-sticky situation. Blood, 2012, 119, 3876-3877.	1.4	8
79	Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multiâ€institutional review. American Journal of Hematology, 2019, 94, 461-466.	4.1	8
80	Human mutational constraint as a tool to understand biology of rare and emerging bone marrow failure syndromes. Blood Advances, 2020, 4, 5232-5245.	5.2	8
81	An Update on Pediatric Immune Thrombocytopenia (ITP): Differentiating Primary ITP, IPD, and PID. Blood, 2021, , .	1.4	8
82	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. Blood, 2015, 126, 73-73.	1.4	6
83	MYH9â€macrothrombocytopenia caused by a novel variant (E1421K) initially presenting as apparent neonatal alloimmune thrombocytopenia. Pediatric Blood and Cancer, 2018, 65, e26949.	1.5	5
84	Extreme thrombocytosis is associated with critical illness and young age, but not increased thrombotic risk, in hospitalized pediatric patients. Journal of Thrombosis and Haemostasis, 2020, 18, 3352-3358.	3.8	5
85	Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences. Blood, 2020, 136, 640-643.	1.4	5
86	Platelet factorÂ4 platelet levels are inversely correlated with steadyâ€state platelet counts and with platelet transfusion needs in pediatric leukemia patients. Journal of Thrombosis and Haemostasis, 2012, 10, 1442-1446.	3.8	4
87	They're not your daddy's inherited platelet disorders anymore. Journal of Thrombosis and Haemostasis, 2013, 11, 2037-2038.	3.8	4
88	Standardization of prophylactic platelet transfusion dosing in a pediatric oncology population: a quality improvement project. Transfusion, 2018, 58, 2836-2840.	1.6	4
89	Immunomodulatory Second-Line Therapies for Immune Thrombocytopenia. Hamostaseologie, 2019, 39, 266-271.	1.9	4
90	Genetic variants in tollâ€like receptor 4 are associated with lack of steroidâ€responsiveness in pediatric ITP patients. American Journal of Hematology, 2020, 95, 395-400.	4.1	4

#	Article	IF	Citations
91	Quality of life is an important indication for secondâ€line treatment in children with immune thrombocytopenia. Pediatric Blood and Cancer, 2021, 68, e29023.	1.5	4
92	Updates in diagnosis of the inherited platelet disorders. Current Opinion in Hematology, 2020, 27, 333-340.	2.5	3
93	Thrombocytosis in an infant with a TRPV4 mutation: a case report. Platelets, 2021, 32, 429-431.	2.3	3
94	SARSâ€CoVâ€2 vaccination in pediatric patients with immune thrombocytopenia. Pediatric Blood and Cancer, 2022, 69, e29760.	1.5	3
95	Defective RAB31-mediated megakaryocytic early endosomal trafficking of VWF, EGFR, and M6PR inRUNX1deficiency. Blood Advances, 2022, 6, 5100-5112.	5.2	3
96	TPO-mimetics and myelofibrosis? A reticulin question!. Blood, 2009, 114, 3722-3723.	1.4	2
97	More than one pathway: novel treatment for ITP. Blood, 2019, 133, 629-630.	1.4	2
98	Intravenous immunoglobulin use in children with ITP does not affect development of chronic disease. Journal of Pediatrics, 2019, 204, 320-323.	1.8	2
99	Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders. Hematology American Society of Hematology Education Program, 2020, 2020, 76-81.	2.5	2
100	Report of a â€˜consensusâ€™ on the lines of therapy for primary immune thrombocytopenia in adults, promoted by the Italian Gruppo di Studio delle Piastrine. Platelets, 2020, 31, 461-473.	2.3	2
101	Negative Paracrine Effect of Platelet Factor 4 on Megakaryopoiesis Occurs through Lipoprotein Related Protein Receptor-1 on Megakaryocytes.. Blood, 2007, 110, 97-97.	1.4	2
102	Megakaryocytes Regulate Hematopoietic Stem Cell Quiescence Via PF4 Secretion. Blood, 2013, 122, 3-3.	1.4	2
103	Targeting mTOR Signaling Leads To Complete and Durable Responses In Children With Multi-Lineage Autoimmune Cytopenias, Including ALPS, SLE, Evans and CVID. Blood, 2013, 122, 330-330.	1.4	2
104	Megakaryocytes Exchange Significant Levels of Their Alpha-Granular PF4 with Their Environment. Blood, 2014, 124, 1432-1432.	1.4	2
105	Honing in on the Range: Using the Electronic Medical Record to Establish Normal Reference Ranges for Pediatric Coagulation Testing. Blood, 2015, 126, 4450-4450.	1.4	2
106	The Immature Reticulocyte Fraction As an Aid in the Diagnosis and Prognosis of Parvovirus B19 Infection in Sickle Cell Disease. Blood, 2018, 132, 3678-3678.	1.4	2
107	Childhood ITP: knowing when to worry?. Blood, 2009, 114, 4758-4759.	1.4	1
108	Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia. Pediatric Health, Medicine and Therapeutics, 2016, 7, 39.	1.6	1

#	Article	IF	Citations
109	Neonatal platelet count trends during inhaled nitric oxide therapy. British Journal of Haematology, 2020, 188, e28-e30.	2.5	1
110	Thromboelastography Changes of Whole Blood Compared to Blood Component Transfusion in Infant Craniosynostosis Surgery. Journal of Craniofacial Surgery, 2022, 33, 129-133.	0.7	1
111	Inherited Thrombocytopenias. , 2007, , 985-998.		1
112	RAB31-Mediated Endosomal Trafficking Is Defective in RUNX1 Haplodeficiency. Blood, 2018, 132, 519-519.	1.4	1
113	The ITP Natural History Study Registry: Preliminary Findings on the Immune Thrombocytopenia Patient Experience. Blood, 2018, 132, 4979-4979.	1.4	1
114	Can Immature Platelet Fraction (IPF) be Used to Assess Bleeding Risk in Pediatric Immune Thrombocytopenia (ITP) and to Differentiate ITP from Bone Marrow Failure/Aplastic Anemia? A Retrospective Analysis. Blood, 2015, 126, 3474-3474.	1.4	1
115	Utility of Whole Exome Sequencing in Diagnosis of Pediatric Platelet Disorders: A Subanalysis of the Pediseq Study. Blood, 2016, 128, 3726-3726.	1.4	1
116	Incidence of Hemolytic Events after Exposure to Triggering Medications in Pediatric Patients with G6PD Deficiency. Blood, 2016, 128, 4810-4810.	1.4	1
117	Analysis of the Frequency of Spontaneous, Functionally-Significant Mutations in Genes Associated with Platelet Disorders in >120,000 Healthy Individuals. Blood, 2018, 132, 2438-2438.	1.4	1
118	Racial Variation in ITP Prevalence and Rate of Chronic Disease Suggests Biological Differences. Blood, 2019, 134, 387-387.	1.4	1
119	The Effect of "Pathway" to Diagnosis for Childhood ITP on Caregiver Quality of Life at Time of Diagnosis. Blood, 2019, 134, 2174-2174.	1.4	1
120	Dose Escalation Trial of Desulfated Heparin (ODSH) in Septic Peritonitis. Frontiers in Veterinary Science, 2022, 9, 862308.	2.2	1
121	Cover Image, Volume 176A, Number 10, October 2018. , 2018, 176, i-i.		0
122	The Treatment of Immune Thrombocytopenia. , 2018, , 45-80.		0
123	EVALUATION OF A CLINICAL PRACTICE PATHWAY FOR THE MANAGEMENT OF ACUTE CATHETER-RELATED VENOUS THROMBOEMBOLISM IN PEDIATRIC CARDIOLOGY PATIENTS: YEAR FOUR REVIEW. Journal of the American College of Cardiology, 2019, 73, 628.	2.8	0
124	Inherited Thrombocytopenias. , 2019, , 849-861.		0
125	Congenital Thrombocytopenia. , 2019, , 571-580.		0
126	Platelet Factor 4 Regulates Platelet Count In Vivo: Implications for Platelet Recovery after Cytotoxic Therapy.. Blood, 2005, 106, 3144-3144.	1.4	0

#	Article	IF	Citations
127	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. Blood, 2010, 116, 2509-2509.	1.4	0
128	Influence Of Updated ASH Guidelines On Practice Patterns In Management Of Newly Diagnosed Childhood ITP, 2007-2012. Blood, 2013, 122, 772-772.	1.4	0
129	Detecting 22q11.2 Deletion Syndrome Using Flow Cytometry. Blood, 2014, 124, 4207-4207.	1.4	0
130	Conditional Knockout of LRP1 in Murine Megakaryocytes and Its Affects on Platelet Factor 4 Biology in Megakaryocytes. Blood, 2014, 124, 4150-4150.	1.4	0
131	Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. Blood, 2016, 128, 1008-1008.	1.4	0
132	Expression Differences Distinguish Pediatric Acute and Chronic ITP Using RNA Sequencing. Blood, 2018, 132, 127-127.	1.4	0
133	Comparison of LTA Versus Wbila in Pediatric Patients with Suspected Platelet Function Disorders. Blood, 2018, 132, 3762-3762.	1.4	0
134	Targeting Immune Dysregulation in Childhood Evans Syndrome. Blood, 2018, 132, 3564-3564.	1.4	0
135	The Role of PF4 Antibodies in Pediatric Sars-Cov-2 Infections. Blood, 2021, 138, 1004-1004.	1.4	0
136	Immature Platelet Fraction Does Not Correlate with Treatment Response in Immune Thrombocytopenia. Blood, 2021, 138, 1024-1024.	1.4	0
137	Anxiety in Adult Patients Living with ITP Stratified across Different Treatment Types and Groups. Blood, 2020, 136, 18-18.	1.4	0
138	Evidence of Microangiopathy in Children with Sars-Cov-2 Regardless of Clinical Presentation. Blood, 2020, 136, 28-29.	1.4	0
139	Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method. Blood, 2020, 136, 6-8.	1.4	0